Upfront intensive treatment analysis of the Italian Cohort Study on FLT3‐mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real‐life setting
Sign Up to like & getrecommendations! Published in 2025 at "Cancer"
DOI: 10.1002/cncr.35824
Abstract: The addition of a FLT3 inhibitor (FLT3i) to standard chemotherapy to treat fit newly diagnosed (ND) patients with FLT3‐mutated acute myeloid leukemia (AML) represents the standard of care resulting from clinical trial results. However, evidence… read more here.
Keywords: standard chemotherapy; flt3; addition; flt3 mutated ... See more keywords
Central nervous system relapse after allogeneic HCT in FLT3-mutated AML
Sign Up to like & getrecommendations! Published in 2024 at "Annals of Hematology"
DOI: 10.1007/s00277-024-06106-y
Abstract: Central nervous system (CNS) relapse in acute myeloid leukemia (AML) is rare, but prognostically extremely unfavorable and associated with very high mortality rates. Aim of our single-center study was to define risk factors for CNS… read more here.
Keywords: relapse; central nervous; mutated aml; hct ... See more keywords
Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-021-02006-7
Abstract: Until recently, no effective targeted therapies for FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML) were available in Japan. The FLT3 inhibitor, gilteritinib, was approved in Japan for patients with FLT3mut+ R/R AML based on… read more here.
Keywords: relapsed refractory; gilteritinib; refractory acute; myeloid leukemia ... See more keywords
4-Hydroxyphenyl Retinamide Preferentially Targets FLT3 Mutated Acute Myeloid Leukemia via ROS Induction and NF-κB Inhibition
Sign Up to like & getrecommendations! Published in 2020 at "Current Medical Science"
DOI: 10.1007/s11596-020-2259-0
Abstract: FMS-like tyrosine kinase 3 (FLT3) mutation is strongly associated with poor prognosis in acute myeloid leukemia (AML). Though many FLT3 inhibitors have been developed for clinical application with 34%–56% complete remission rate, patients would develop… read more here.
Keywords: hydroxyphenyl retinamide; myeloid leukemia; flt3 mutated; aml cells ... See more keywords
Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis
Sign Up to like & getrecommendations! Published in 2025 at "Blood Cancer Journal"
DOI: 10.1038/s41408-025-01353-2
Abstract: INTRODUCTION Treatment of relapsed-refractory (R/R) FLT3 mut AML is an unmet need. Use of gilteritinib monotherapy in the ADMIRAL trial resulted in a modest prolongation of overall survival (OS) from 5.6 months to 9.3 months… read more here.
Keywords: gilteritinib; combination; gilteritinib combinations; single center ... See more keywords
Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2022.2054801
Abstract: ABSTRACT Introduction FLT3 inhibitors have been recently introduced as novel treatment targets in patients with FLT3-mutated acute myeloid leukemia (AML). Midostaurin is an oral multikinase inhibitor that targets multiple receptor tyrosine kinases including FLT3 and… read more here.
Keywords: mutated acute; flt3 mutated; acute myeloid; midostaurin ... See more keywords
Revisiting the prognostic role of FLT3 mutations in acute myelogenous leukemia
Sign Up to like & getrecommendations! Published in 2023 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2023.2202849
Abstract: ABSTRACT Introduction Approximately one-third of patients with acute myelogenous leukemia (AML) harbor mutations in the fms-like tyrosine kinase 3 (FLT3) gene. The features regarding prognostic impact of FLT3 mutated AML have been widely investigated and… read more here.
Keywords: flt3; myelogenous leukemia; mutated aml; acute myelogenous ... See more keywords
Interim results from a postmarketing surveillance study of patients with FLT3-mutated relapsed/refractory AML treated with the FLT3 inhibitor gilteritinib in Japan
Sign Up to like & getrecommendations! Published in 2022 at "Japanese Journal of Clinical Oncology"
DOI: 10.1093/jjco/hyac069
Abstract: Abstract Objective Gilteritinib received approval for the treatment of FLT3-mutated relapsed or refractory acute myeloid leukemia in Japan in 2018. In accordance with regulatory requirements, we conducted a multicenter, observational surveillance of gilteritinib use in… read more here.
Keywords: surveillance; flt3 mutated; mutated relapsed; relapsed refractory ... See more keywords
Long Term Follow-up Data after Consolidation Therapy with Ponatinib in Combination with Cytarabine in Patients with FLT3 Mutated Acute Myeloid Leukemia in First Complete Remission
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-209998
Abstract: Background Ponatinib is a third-generation tyrosine kinase inhibitor targeting the BCR::ABL1 tyrosine kinase domain. Despite low activity against FLT3 based on the IC50 value (FLT3 IC50: 12.6 nM), ponatinb has been reported to have significant… read more here.
Keywords: dose; cohort; consolidation; ponatinib ... See more keywords
Enhanced Mitochondrial Priming By Momelotinib Confers Superior In Vivo Efficacy in Combination with Venetoclax Compared to Gilteritinib or Ruxolitinib
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-211412
Abstract: Introduction. Acute Myeloid Leukemia (AML) is a complex hematologic malignancy marked by significant genetic heterogeneity, with FLT3 mutations being among the most common and prognostically unfavorable alterations. Despite advancements in targeted therapies, FLT3-mutated AML remains… read more here.
Keywords: gilteritinib ruxolitinib; combination; mitochondrial priming; momelotinib ... See more keywords
Maintenance treatment with gilteritinib suppresses post-transplant relapse in relapsed/refractory FLT3-mutated acute myeloid leukemia: A Japanese nationwide registry study
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-4289
Abstract: Background: Gilteritinib, a FLT3 inhibitor, is widely used for relapse or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML). However, its safety and effectiveness as maintenance therapy following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in real-world… read more here.
Keywords: gilteritinib; relapse; maintenance; group ... See more keywords